These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 33726696)
1. Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy. Fang R; Wang H; Li Y; Liu YM; Wei WB BMC Ophthalmol; 2021 Mar; 21(1):137. PubMed ID: 33726696 [TBL] [Abstract][Full Text] [Related]
2. Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy. Demirci H; Saponara F; Khan A; Niziol LM; Lee C; Hayman JA; Comer G; Musch DC Middle East Afr J Ophthalmol; 2015; 22(1):103-7. PubMed ID: 25624683 [TBL] [Abstract][Full Text] [Related]
3. Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma. Mruthyunjaya P; Seider MI; Stinnett S; Schefler A; Ophthalmology; 2017 Oct; 124(10):1532-1539. PubMed ID: 28549517 [TBL] [Abstract][Full Text] [Related]
4. [The clinical observation of external scleral plaque radiotherapy in patients with uveal melanoma]. Liu YM; Zhou N; Wei WB; Wang P Zhonghua Yan Ke Za Zhi; 2020 Sep; 56(9):670-675. PubMed ID: 32907299 [No Abstract] [Full Text] [Related]
5. Scleral necrosis in patients with posterior uveal melanomas evaluated by transcleral fine needle aspiration biopsy and treated by 125I plaque. Correa ZM; Huth B; Augsburger JJ Arq Bras Oftalmol; 2018; 81(4):330-335. PubMed ID: 29995126 [TBL] [Abstract][Full Text] [Related]
6. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534 [TBL] [Abstract][Full Text] [Related]
7. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Toivonen P; Kivelä T Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837 [TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy. Wang H; Zhang R; Wang Y; Chen R; Liu Y; Li Y; Wei W BMC Ophthalmol; 2022 Apr; 22(1):163. PubMed ID: 35397506 [TBL] [Abstract][Full Text] [Related]
12. Regression of uveal melanoma after ru-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography. Lee CS; Lee SC; Lee K; Kwon HJ; Yi JH; Cho A Retina; 2014 Jan; 34(1):182-7. PubMed ID: 23719400 [TBL] [Abstract][Full Text] [Related]
13. Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height. Gupta K; McCannel CA; Kamrava M; Lamb J; Almanzor RD; McCannel TA Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1371-8. PubMed ID: 26907932 [TBL] [Abstract][Full Text] [Related]
17. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Puusaari I; Heikkonen J; Kivelä T Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045 [TBL] [Abstract][Full Text] [Related]
18. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Quivey JM; Augsburger J; Snelling L; Brady LW Cancer; 1996 Jun; 77(11):2356-62. PubMed ID: 8635107 [TBL] [Abstract][Full Text] [Related]
20. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool. Aziz HA; Singh N; Bena J; Wilkinson A; Singh AD JAMA Ophthalmol; 2016 Jun; 134(6):615-20. PubMed ID: 27101414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]